Dr. Oz, the head of CMS, is now calling the plans "CHOICE Arrangements" and asking states to do more to support them.

In other words, the entry of biosimilars into a reference product's market does not guarantee patient savings. Benefit design ...

In a recent survey by the Commonwealth Fund, around three-quarters of respondents cited either the cost of premiums or high out-of-pocket costs as the most important problem in the U.S. health care ...

DeRemer had an inappropriate relationship with a DOL special agent and drank on federal property without proper authorization ...

A Milwaukee hospital alleges CVS used its control of a PBM, specialty pharmacy and third-party administrator to reduce ...

"Understanding the financial challenges LGBTQ+ adults face when accessing health care can help identify persistent gaps in ...

State lawmakers and regulators might be able to clear barriers to use reference-based pricing in the market for fully insured group health coverage. But the federal Employee Retirement Income Security ...

Nearly 70% of the estimate rests on payments above an insurer-calculated benchmark that a federal appeals court recently ...

This not only would be the fifth-consecutive year of elevated cost growth but also would be the largest annual increase since ...

Aon today announced plans to buy USI Insurance Services from KKR for $17 billion in cash. Aon executives talked about how ...

For brokers helping clients prepare for open enrollment, those questions point to something that can easily be overlooked during planning: the benefits administration experience itself is part of the ...